インドネシアのがん疼痛管理市場予測　2024-2032年

Report Overview

KEY FINDINGS
The Indonesia cancer pain management market is expected to grow with a CAGR of 6.16% during the forecast period 2024-2032.

インドネシアのがん疼痛管理市場は、2024年から2032年の予測期間中に6.16%のCAGRで成長すると予想されています。

MARKET INSIGHTS
Indonesia is experiencing a rise in cancer cases across its diverse population, with prevalent types including breast, cervical, lung, and colorectal cancers. This increase underscores a growing need for effective pain management solutions to enhance patient quality of life. According to the Global Cancer Observatory, Indonesia recorded 408,661 new cancer cases in 2022, highlighting the significant burden of the disease. As cancer rates continue to climb, there is an escalating demand for improved pain management strategies.
One contributing factor to this demand is Indonesia’s expanding elderly population, which numbered nearly 19 million in 2022. This demographic shift reflects broader trends in healthcare and increased life expectancy. Despite these advancements, access to advanced pain management treatments remains limited outside major cities, exacerbating disparities in healthcare resources across different regions of the country. The need for specialized pain management services, including palliative care, remains critical but often falls short in many areas.
The regulatory landscape and healthcare policies also play a crucial role in shaping the Indonesia cancer pain management market. Ongoing efforts to enhance healthcare services and access to cancer pain relief drugs are underway, yet there is a clear opportunity for further policy development and implementation. Government initiatives aimed at strengthening cancer care infrastructure, supporting healthcare providers, and promoting advancements in cancer treatment and pain management technologies are essential steps toward meeting these challenges comprehensively.

REPORT SYNOPSIS

SEGMENTATION ANALYSIS
The report on the Indonesia cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:
• Opioids
• Morphine
• Fentanyl
• Other Morphines
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Nerve Blockers
Market by Disease Indication:
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Other Disease Indications
Inkwood Research’s report on the Indonesia cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.
COMPETITIVE ANALYSIS
Key players operating in the Indonesia cancer pain management market include Abbott, Hisamitsu Pharmaceutical Co Ltd, Pfizer, Teva Pharmaceutical Industries, PT Kalventis Sinergi Farma (Sanofi), etc.
Pfizer Inc is a biopharmaceutical firm that creates healthcare solutions ranging from preventing diseases to the treatment of chronic ailments and rare disorders. Pharmaceuticals, vaccines, and consumer healthcare are its three main business segments. Pfizer’s global activities include a substantial presence in North America, Europe, Asia, Latin America, and other locations. Its global headquarters are in New York City, the United States.

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT — INDONESIA
2.3. COUNTRY ANALYSIS — INDONESIA
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON THE INDONESIA CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. INNOVATIONS IN PALLIATIVE CARE
2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. RISING CANCER RATES IN INDONESIA
3.1.2. GROWING ELDERLY POPULATION
3.1.3. ENHANCED HEALTHCARE INFRASTRUCTURE
3.2. KEY RESTRAINTS
3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
3.2.2. HIGH COST OF TREATMENT
3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN INDONESIA
4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING — INDONESIA
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH & DEVELOPMENT
4.5.2. REGULATORY APPROVAL
4.5.3. MANUFACTURING
4.5.4. DISTRIBUTION
4.5.5. END-USERS
5. MARKET BY DRUG TYPE
5.1. OPIOIDS
5.2. MORPHINE
5.2.1. FENTANYL
5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS
6. MARKET BY DISEASE INDICATION
6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. ABBOTT
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCTS
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. HISAMITSU PHARMACEUTICAL CO LTD
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCTS
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. PFIZER
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCTS
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. TEVA PHARMACEUTICAL INDUSTRIES
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCTS
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. PT KALVENTIS SINERGI FARMA (SANOFI)
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCTS
7.2.5.3. STRENGTHS & CHALLENGES

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – CANCER PAIN MANAGEMENT
TABLE 2: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

List of Figures

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING – INDONESIA
FIGURE 4: VALUE CHAIN ANALYSIS
FIGURE 5: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023
FIGURE 6: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 7: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)
FIGURE 8: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023
FIGURE 9: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)
FIGURE 10: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)
FIGURE 11: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 12: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)
FIGURE 13: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)
FIGURE 14: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: INDONESIA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023
FIGURE 16: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)
FIGURE 17: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)
FIGURE 18: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 19: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)
FIGURE 21: INDONESIA CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧